Symptom profiles compatible with disorders of gut-brain interaction (DGBI) in organic gastrointestinal diseases: A global population-based study.
coeliac disease
disorders of gut‐brain interaction
epidemiology
functional disorders
gastroesophageal reflux disease
inflammatory bowel disease
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
08 Jul 2024
08 Jul 2024
Historique:
received:
08
03
2024
accepted:
29
04
2024
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
8
7
2024
Statut:
aheadofprint
Résumé
Patients with organic gastrointestinal (GI) diseases and diabetes mellitus (DM) can have concomitant disorders of gut-brain interaction (DGBI). This study aimed to compare the global prevalence of DGBI-compatible symptom profiles in adults with and without self-reported organic GI diseases or DM. Data were collected in a population-based internet survey in 26 countries, the Rome Foundation Global Epidemiology Study (n = 54,127). Individuals were asked if they had been diagnosed by a doctor with gastroesophageal reflux disease, peptic ulcer, coeliac disease, inflammatory bowel disease (IBD), diverticulitis, GI cancer or DM. Individuals not reporting the organic diagnosis of interest were included in the reference group. DGBI-compatible symptom profiles were based on Rome IV diagnostic questions. Odds ratios (ORs [95% confidence interval]) were calculated using mixed logistic regression models. Having one of the investigated organic GI diseases was linked to having any DGBI-compatible symptom profile ranging from OR 1.64 [1.33, 2.02] in GI cancer to OR 3.22 [2.80, 3.69] in IBD. Those associations were stronger than for DM, OR 1.26 [1.18, 1.35]. Strong links between organic GI diseases and DGBI-compatible symptom profiles were seen for corresponding (e.g., IBD and bowel DGBI) and non-corresponding (e.g., IBD and esophageal DGBI) anatomical regions. The strongest link was seen between fecal incontinence and coeliac disease, OR 6.94 [4.95, 9.73]. After adjusting for confounding factors, associations diminished, but persisted. DGBI-compatible symptom profiles are more common in individuals with self-reported organic GI diseases and DM compared to the general population. The presence of these concomitant DGBIs should be considered in the management of organic (GI) diseases.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with organic gastrointestinal (GI) diseases and diabetes mellitus (DM) can have concomitant disorders of gut-brain interaction (DGBI).
OBJECTIVE
OBJECTIVE
This study aimed to compare the global prevalence of DGBI-compatible symptom profiles in adults with and without self-reported organic GI diseases or DM.
METHODS
METHODS
Data were collected in a population-based internet survey in 26 countries, the Rome Foundation Global Epidemiology Study (n = 54,127). Individuals were asked if they had been diagnosed by a doctor with gastroesophageal reflux disease, peptic ulcer, coeliac disease, inflammatory bowel disease (IBD), diverticulitis, GI cancer or DM. Individuals not reporting the organic diagnosis of interest were included in the reference group. DGBI-compatible symptom profiles were based on Rome IV diagnostic questions. Odds ratios (ORs [95% confidence interval]) were calculated using mixed logistic regression models.
RESULTS
RESULTS
Having one of the investigated organic GI diseases was linked to having any DGBI-compatible symptom profile ranging from OR 1.64 [1.33, 2.02] in GI cancer to OR 3.22 [2.80, 3.69] in IBD. Those associations were stronger than for DM, OR 1.26 [1.18, 1.35]. Strong links between organic GI diseases and DGBI-compatible symptom profiles were seen for corresponding (e.g., IBD and bowel DGBI) and non-corresponding (e.g., IBD and esophageal DGBI) anatomical regions. The strongest link was seen between fecal incontinence and coeliac disease, OR 6.94 [4.95, 9.73]. After adjusting for confounding factors, associations diminished, but persisted.
CONCLUSION
CONCLUSIONS
DGBI-compatible symptom profiles are more common in individuals with self-reported organic GI diseases and DM compared to the general population. The presence of these concomitant DGBIs should be considered in the management of organic (GI) diseases.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Takeda
Organisme : Takeda Israel
Organisme : Romanian Society of Neurogastroenterology
Organisme : Ironwood
Organisme : Shire
Organisme : Allergan
Informations de copyright
© 2024 The Author(s). United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Aziz I, Simrén M. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. Lancet Gastroenterol Hepatol. 2021;6(2):139–148. https://doi.org/10.1016/s2468‐1253(20)30212‐0
Törnblom H, Abrahamsson H, Barbara G, Hellström PM, Lindberg G, Nyhlin H, et al. Inflammation as a cause of functional bowel disorders. Scand J Gastroenterol. 2005;40(10):1140–1148. https://doi.org/10.1080/00365520510023657
Schiepatti A, Maimaris S, Lusetti F, Scalvini D, Minerba P, Cincotta M, et al. High prevalence of functional gastrointestinal disorders in celiac patients with persistent symptoms on a gluten‐free diet: a 20‐year follow‐up study. Dig Dis Sci. 2022;68(8):3374–3382. https://doi.org/10.1007/s10620‐022‐07727‐x
Sainsbury A, Sanders DS, Ford AC. Prevalence of irritable bowel syndrome‐type symptoms in patients with celiac disease: a meta‐analysis. Clin Gastroenterol Hepatol. 2013;11(4):359–365.e1. https://doi.org/10.1016/j.cgh.2012.11.033
Hsu SM, Lin HJ, Lin MC, Huang ST. Increased incidence and recurrence rates of acute diverticulitis in patients with irritable bowel syndrome. Colorectal Dis. 2020;22(12):2181–2190. https://doi.org/10.1111/codi.15325
Mavroudis G, Simren M, Jonefjäll B, Öhman L, Strid H. Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease. Therap Adv Gastroenterol. 2019;12:1756284819827689. https://doi.org/10.1177/1756284819827689
Parker S, Palsson O, Sanders DS, Simren M, Sperber AD, Törnblom H, et al. Functional gastrointestinal disorders and associated health impairment in individuals with celiac disease. Clin Gastroenterol Hepatol. 2022;20(6):1315–1325.e4. https://doi.org/10.1016/j.cgh.2021.07.026
Van Nieuwenhove T, Rasschaert G, Kharagjitsingh A, Keymeulen B, Reynaert H, Kindt S. The prevalence of disorders of the gut‐brain axis in type 2 diabetes mellitus patients with metabolic dysfunction‐associated fatty liver disease: an observational study. Acta Gastroenterol Belg. 2021;84(4):541–547. https://doi.org/10.51821/84.4.003
Hartstra AV, Bouter KE, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015;38(1):159–165. https://doi.org/10.2337/dc14‐0769
Rampanelli E, Nieuwdorp M. Gut microbiome in type 1 diabetes: the immunological perspective. Expert Rev Clin Immunol. 2023;19(1):93–109. https://doi.org/10.1080/1744666x.2023.2150612
Sperber AD, Freud T, Aziz I, Palsson OS, Drossman DA, Dumitrascu DL, et al. Greater overlap of Rome IV disorders of gut‐brain interactions leads to increased disease severity and poorer quality of life. Clin Gastroenterol Hepatol. 2022;20(5):e945–e956. https://doi.org/10.1016/j.cgh.2021.05.042
Frändemark Å, Törnblom H, Hreinsson JP, Andresen V, Benninga MA, Corazziari ES, et al. Work productivity and activity impairment in disorders of gut‐brain interaction: data from the Rome Foundation Global Epidemiology Study. United Eur Gastroenterol J. 2023;11(6):503–513. https://doi.org/10.1002/ueg2.12425
Hreinsson JP, Wong RKM, Tack J, Whorwell P, Benninga MA, Andresen V, et al. A comparative study of disorders of gut‐brain interaction in Western Europe and Asia based on the Rome foundation global epidemiology study. Neuro Gastroenterol Motil. 2023;35(6):e14566. https://doi.org/10.1111/nmo.14566
Colomier E, Melchior C, Algera JP, Hreinsson JP, Störsrud S, Törnblom H, et al. Global prevalence and burden of meal‐related abdominal pain. BMC Med. 2022;20(1):71. https://doi.org/10.1186/s12916‐022‐02259‐7
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160(1):99–114.e3. https://doi.org/10.1053/j.gastro.2020.04.014
Palsson OS, Whitehead WE, van Tilburg MA, Chang L, Chey W, Crowell MD, et al. Rome IV diagnostic questionnaires and tables for investigators and clinicians. Gastroenterology. 2016;150(6):1481–1491. https://doi.org/10.1053/j.gastro.2016.02.014
Kroenke K, Spitzer RL, Williams JB. The PHQ‐15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64(2):258–266. https://doi.org/10.1097/00006842‐200203000‐00008
Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra‐brief screening scale for anxiety and depression: the PHQ‐4. Psychosomatics. 2009;50(6):613–621. https://doi.org/10.1176/appi.psy.50.6.613
Available from: https://www.codetechnology.com/blog/promis‐global‐10/
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. L. Elbaum Associates ed1988.
Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome‐type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1053–1062. https://doi.org/10.1016/s2468‐1253(20)30300‐9
Choung RS, Richard Locke G, 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Multiple functional gastrointestinal disorders linked to gastroesophageal reflux and somatization: a population‐based study. Neuro Gastroenterol Motil. 2017;29(7). https://doi.org/10.1111/nmo.13041
Fairbrass KM, Lovatt J, Barberio B, Yuan Y, Gracie DJ, Ford AC. Bidirectional brain‐gut axis effects influence mood and prognosis in IBD: a systematic review and meta‐analysis. Gut. 2022;71(9):1773–1780. https://doi.org/10.1136/gutjnl‐2021‐325985
Petrik M, Palmer B, Khoruts A, Vaughn B. Psychological features in the inflammatory bowel disease‐irritable bowel syndrome overlap: developing a preliminary understanding of cognitive and behavioral factors. Crohns Colitis 360. 2021;3(3):otab061. https://doi.org/10.1093/crocol/otab061
Geeraerts A, Van Houtte B, Clevers E, Geysen H, Vanuytsel T, Tack J, et al. Gastroesophageal reflux disease‐functional dyspepsia overlap: do birds of a feather flock together? Am J Gastroenterol. 2020;115(8):1167–1182. https://doi.org/10.14309/ajg.0000000000000619
Menees SB, Almario CV, Spiegel BMR, Chey WD. Prevalence of and factors associated with fecal incontinence: results from a population‐based survey. Gastroenterology. 2018;154(6):1672–1681.e3. https://doi.org/10.1053/j.gastro.2018.01.062
Jonefjäll B, Strid H, Ohman L, Svedlund J, Bergstedt A, Simren M. Characterization of IBS‐like symptoms in patients with ulcerative colitis in clinical remission. Neuro Gastroenterol Motil. 2013;25(9):756. https://doi.org/10.1111/nmo.12163
Najafi F, Moradinazar M, Hamzeh B, Rezaeian S. The reliability of self‐reporting chronic diseases: how reliable is the result of population‐based cohort studies. J Prev Med Hyg. 2019;60(4):e349–e353.
Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):14790. https://doi.org/10.1038/s41598‐020‐71908‐9
Strate LL, Morris AM. Epidemiology, pathophysiology, and treatment of diverticulitis. Gastroenterology. 2019;156(5):1282–1298.e1. https://doi.org/10.1053/j.gastro.2018.12.033
Rose TC, Pennington A, Kypridemos C, Chen T, Subhani M, Hanefeld J, et al. Analysis of the burden and economic impact of digestive diseases and investigation of research gaps and priorities in the field of digestive health in the European Region‐White Book 2: executive summary. United Eur Gastroenterol J. 2022;10(7):657–662. https://doi.org/10.1002/ueg2.12298